X4 Pharmaceuticals Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $2.879M Beat $2.300M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 76.81 percent increase over losses of $(0.69) per share
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 76.81 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $2.879 million which beat the analyst consensus estimate of $2.300 million by 25.17 percent. This is a 63.12 percent increase over sales of $1.765 million the same period last year.